We report on the virtual screening, synthesis, and biological evaluation of new furan derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual screening procedure was applied to screen the Enamine database, identifying two compounds, I and III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent MbtI inhibitor reported to date (Ki = 5.3 µM). Moreover, compound 1a showed a promising antimycobacterial activity (MIC 99 = 156 µM), which is conceivably related to mycobactin biosynthesis inhibition.
INTRODUCTION
Tuberculosis (TB), caused by the pathogen Mycobacterium tuberculosis (Mtb), is one of the deadliest infectious diseases worldwide, with about 1.7 million deaths reported in 2016 [1] . New TB drugs are needed because of the complexity and toxicity of the current TB therapeutic regimens and to provide alternatives to contrast the emergence of multidrugresistant (MDR) and extensively drug-resistant (XDR) Mtb strains [2, 3] . The investigation of novel pharmacological targets, such as InhA, MmpL3, DprE1 and QcrB, plays a fundamental role in the development of new potential antitubercular agents [4] . Since the most promising targets are membrane proteins, the identified hit compounds may also interfere with the integrity of the host membranes; therefore, the selection of different targets to be tackled is still urgent [5] [6] [7] [8] . In addition, there are a number of novel anti-TB compounds in clinical trial, and two new drugs have been recently approved: delamanid and bedaquiline. Despite these advances, many more TB drug candidates are necessary to sustain an effective and productive drug pipeline [9] . In particular, more information on the effectiveness, safety and tolerability of bedaquiline is urgently required, because its severe side effects (mainly QT prolongation) could be potentially life-threatening [9] . Therefore, the research of new anti-TB drugs that can shorten and simplify current pharmacological therapy is pivotal [10] .
One of the strategies adopted to fight bacterial pathogens is to target the biosynthesis of mycobactins, high-affinity iron-chelating molecules called siderophores [6] . Iron is an essential redox cofactor, involved in several cellular processes, allowing the survival and growth of the mycobacterium in the host. Nevertheless, Mtb is capable of sustaining an infection even in an iron-deficient environment by overcoming it by means of several iron acquisition pathways, among which the synthesis of siderophores plays a key role. Water-soluble carboxymycobactins and lipophilic mycobactins, compounds that vary according to the nature of their lipophilic moiety, are able to solubilize iron and compete with the ironbinding proteins (e.g. transferrin, lactoferrin, ferritin) of the host. While mycobactins remain associated within the cell wall, carboxymycobactins are released outside the outer membrane, where they scavenge iron, making it available for transport into the Mtb cytoplasm [11] . As the bacterial strains unable to produce siderophores lose their ability to grow within macrophages and sustain the infection [12] , there is a considerable interest in deciphering the mechanism of siderophore assembly, with the goal of targeting selected steps for antitubercular drug development. Among the enzymes involved in siderophore biosynthesis [6] , the Mg 2+ -dependent salicylate synthase (MbtI) has been validated as a target for fighting TB [13, 14] . Since MbtI catalyzes the first step of the process by converting chorismate to salicylate via an isochorismate intermediate (Scheme 1), its inhibition leads to a reduced mycobacterial pathogenicity without toxicity issues, due to the absence of this target in the host [15] . The first structural and biochemical characterization of MbtI was reported by Harrison et al. [16] and structural data highlights that the Mg 2+ is coordinated by E297 and E434, as well as the C1 carboxylate of chorismate [13] . Residue K205 assists the attack of water at the chorismate C2 carbon for the isomerization reaction and E252 provides acid catalysis for the elimination of the hydroxyl group from C4 carbon. The positioning of the pyruvate side chain of the substrate is allowed by the interactions with Y385, R405 and G419 [13] . With the aim of identifying new MbtI inhibitors, a receptor-based virtual screening (VS) study was carried out and a preliminary optimization of one of the two identified hits was performed. This study has led to novel chemical entities that could represent an alternative and/or complementary therapy for the treatment of multidrug-resistant strains, opening new avenues to improved clinical outcomes.
RESULTS AND DISCUSSION
Virtual Screening. A VS study, focused on the ligand-MbtI key interactions, was developed. A pharmacophore model was created based on the analysis of the crystal structure of MbtI co-crystallized with 3-(1-carboxyprop-1-enyloxy)-2-hydroxybenzoic acid (Methyl-AMT, PDB code 3VEH) [17] . Figure 1A depicts the interactions of Methyl-AMT inside the MbtI binding site. The carboxylic group of the 2-hydroxy benzoic acid forms an Hbond with the side-chain of Y385; the analysis of different MbtI crystal structures suggests that the position of this residue is highly conserved, and it is important for the interaction of the carboxylic function of the reported MbtI inhibitors. The aromatic ring of the 2-hydroxy benzoic acid shows lipophilic interactions with I207, A362, L404 and a cation-π interaction with K438. The methyl fragment of the 1-carboxyprop-1-enyloxy ligand chain is inserted into a lipophilic pocket mainly delimited by P251, L268, H334 and T361, whereas the second carboxylic group shows an ionic interaction involving K438 and it is compatible with the interaction with the Magnesium ion. Based on these considerations, we built a structurebased pharmacophore taking into account a) the H-bond with Y385, b) the lipophilic interactions of the aromatic ring, c) the methyl fragment and d) the coordination of the carboxylic group with the Magnesium ion. The model, shown in Figure 1B , was generated using the software Ligandscout [18] and comprised (1) an H-bond acceptor feature representing the oxygen atom of the carboxylic fragment interacting with Y385, (2, 3) two hydrophobic features representing the aromatic and methyl substituents and (4) a negative feature representing the carboxylic group of the 1-carboxypropenyl-1-enyloxy fragment. In addition, the pharmacophore model was refined by adding excluded volume spheres mimicking the steric hindrance represented by the MbtI binding site (see Experimental Section for more details). The pharmacophore model was used to screen the Enamine database, comprising about 1 500 000 commercially available compounds, retrieving only compounds matching all the four pharmacophore features and respecting the volume constraints given by the MbtI binding site. By applying this strict filter, only 2050 compounds were further considered and subjected to docking studies. Recently, we have reported an evaluation of the consensus docking approach [19] . Through this approach, one ligand is docked into the target protein by means of multiple docking methods. Then, among the best-ranked poses (originated by the different docking procedures), the binding pose predicted by the largest number of docking methods is considered as the best docking pose. From a qualitative point of view, previous results highlighted that consensus docking was able to predict ligand binding poses better than the single docking evaluations [20] . Furthermore, concerning the VS studies, the results suggested that this approach performed as well as the best available methods found in the literature [20] , and it was also able to experimentally identify new active molecules [21] [22] [23] . The 2050 compounds selected through the pharmacophore filter were subjected to a consensus docking protocol calibrated for the docking of MbtI inhibitors. The MtbI-tuned consensus docking protocol included 5 different docking methods, i.e. Plants and Gold with the four different fitness scoring functions, which were found to be the most reliable procedures among a total of 11 different docking methods, according to self-docking studies performed on six MbtI-ligand co-crystal structures (see Section S1 of Supplementary material for more details). The five selected docking procedures were then applied to the 2050 commercial compounds. For each ligand, the five docking poses predicted by the five docking procedures were clustered together to search for common binding modes. The analysis revealed that only 74 compounds presented a binding pose shared by all the five docking methods and thus reached the maximum consensus level. Therefore, based on the consensus docking filter, only 3.6% of the docked compounds were considered as potential active inhibitors. These results are in agreement with our previous consensus docking calculations reported in literature, which highlighted the high filtering strictness of this procedure. In 2014, we tested the reliability of a consensus docking protocol comprising 10 different procedures by applying this technique on three different targets of the Directory of Useful Decoys (DUD) and at the end of the screening calculations only an average of 0.40% of the starting databases was considered as potentially active [19] . More recently, the whole DUD dataset has been analyzed by means of the same consensus docking approach and an average of 0.44% of the starting databases was considered as potential actives [20] .
Considering that the higher the number of docking methods included in the consensus docking protocol, the higher its filtering strictness, the results obtained with the MtbI-tuned consensus docking protocol are in line with those shown by our previous evaluations. The analysis of the binding mode predicted for the 74 potential MtbI inhibitors identified by the consensus docking protocol revealed that only five compounds still matched the receptorbased pharmacophore model in their docking pose. On these bases, the five compounds were purchased at the highest purity level available from the commercial source (≥ 95%) and subjected to biological assays to evaluate their MbtI inhibitory activity. [24] and to the AMT-series, which is structurally related to isochorismate [14, 15] , showing IC50 values of about 10 μM. In particular, Methyl-AMT, which emerged as the most powerful candidate of the AMT-series, was used as a positive control, showing an IC50 value of 11.6 μM, in agreement with the previously reported values [14, 15] . As shown in Table 1 , one compound was found to be provided with a remarkable activity (compound I, IC50 = 21.1 M), another one displayed a modest activity (compound III, IC50 = 77.6 M), while the three other compounds resulted completely inactive. Compounds I and III were also subjected to molecular dynamics (MD) simulations with explicit water, in order to further analyze their predicted binding mode. Magnesium ion was also included at the entrance of the MbtI active site in order to analyze its interaction with the ligands. Figure 2A shows the predicted binding mode of compound I into the MbtI binding site. The Magnesium ion presents an octahedral coordination geometry: it is bound by a water molecule, one oxygen of the carboxylate groups of E294, E297 and E434 and the two oxygens of the carboxylate of compound I. The furan ring shows an H-bond with K438, whereas the benzene ring, as for Methyl-AMT, exhibits lipophilic interactions with I207, L404
and a cation-π interaction with K438. Finally, the nitro group strongly interacts with Y385 and, furthermore, it forms a second H-bond with the nitrogen backbone of R405. Figure 2B shows In order to further assess the solidity of our VS workflow, a retrospective evaluation was carried out. In particular, as shown in Supplementary material (Sections S2, S3) simpler ligand-based approaches such as fingerprint similarity searches or 3D ligand similarity screenings showed a lower performance in retrieving the most active identified compound (I) from the initial commercial database. Moreover, as shown in Supplementary material (Section S4), the application of the consensus docking approach was found to outperform the single docking methods in identifying compound I from the 2050 ligands selected through the pharmacophore filter.
Structure-activity relationship (SAR) studies.
In this study we considered the most active compound I as starting point for the development of novel MbtI inhibitors to obtain new derivatives showing potent in vitro inhibition. In order to support the importance of each pharmacophoric feature disclosed by the modeling studies, we designed and synthesized analogs to explore the chemical space and to study the structural and functional requirements for the activity against MbtI. We took into account two main points, namely the substitutions at the phenyl ring and the acidic moiety; the results are summarized in Table   2 . By alternatively removing the chlorine atom or the para nitro group from I, we obtained the active derivative 1a and the inactive compound 1b, respectively. When both these substituents were removed (1c), a complete loss of activity was detected. The SAR studies allowed to evidence that compound 1a shows an improved potency with respect to our initial hit I, as it displayed an IC50 value of 7.6 ± 1.6 μM ( Figure 3A) . All data are mean SD of three replicates.
Mtb minimal inhibitory concentration determination (MIC 99 ).
In order to assess its potency, the inhibitor 1a was investigated for its antibacterial activity against M. tuberculosis
H37Rv, together with 2a, on the basis of the higher activity of esters with respect to the carboxylic acids on this parasite, probably owing to a better ability to cross the mycobacterial cell wall [15] . Compound 1a showed a MIC 99 of 156 µM, whereas for 2a we did not detect an improvement of the cellular potency, probably due to its low solubility in the assay medium. It is noteworthy that, to the best of our knowledge, 1a can be considered as one of the MbtI inhibitors showing the best antimycobacterial activity.
Mycobactin biosynthesis inhibition.
To assess if the antitubercular activity is indeed related with iron-uptake inhibition, we used the non-pathogenic M. bovis BCG, whose siderophores closely resemble the structure of Mtb mycobactins [26, 27] . The compound, when assayed against cells grown in the low iron containing Chelated Sauton's medium, showed a MIC value 3-fold lower than against mycobacteria grown in 7H9 medium (80 μM vs 240 μM), suggesting that the mechanism of action of 1a involves iron uptake. Thus, in order to support the correlation of the antitubercular activity of 1a with MbtI inhibition, the effects of the compound on siderophore production were assessed in M. bovis BCG cells, grown in iron-depleted medium and in the presence of different sub-lethal concentrations of compound 1a. To this purpose, the levels of siderophore production were measured using Universal CAS liquid assay [28] and through the mycobactins isolation and quantification.
As shown in Figure S94 
CONCLUSIONS
MbtI is a validated and attractive target for the treatment of tuberculosis, and its inhibition leads to a reduced mycobacterial pathogenicity without toxicity issues, due to the absence of this target in the host. Starting from the computational analysis of the interaction between In conclusion, the analysis of the hypothetical binding mode of this class of compounds suggested potential points of modification that led to significant developments, and that could be further explored to increase the potency of these derivatives.
EXPERIMENTAL SECTION:
Pharmacophore model generation. One of the main drawbacks of the VS consensus docking approach is the required computing time, because by using this method a whole data set of molecules should be subjected to different docking procedures [19] . Therefore, in order to reduce the number of compounds to be analyzed, a pharmacophore screening was used as a prefilter. The pharmacophore hypothesis was built on the basis of the 3D structure of MbtI co-crystallized with methyl-AMT (PDB code 3VEH) [17] . The software The use of Gold, with the four different fitness functions, and Plants resulted to be the most reliable ones as they showed an average RMSD lower than 2.0 Å. For all the docking procedures the region of interest for the docking studies was defined in such a manner that it contained all residues that stayed within 10 Å from the ligand in the X-ray structure.
Gold. The ''allow early termination'' command was deactivated, while the possibility for the ligand to flip ring corners was activated. For all other parameters, Gold defaults were used and the ligands were subjected to 30 genetic algorithm runs. Four docking analyses were carried out, corresponding to the four implemented fitness functions.
Plants. This docking software uses Ant Colony Optimization, a state-of the-art global optimization algorithm to find minima of a scoring function representing favorable complex structures [30, 31] . ChemPLP scoring function was employed to score protein-ligand interactions as well as intra-ligand clash terms. Standard settings for all parameters were used for the scoring function and the optimization algorithm (search speed setting:
''speed1'').
Consensus docking evaluation. By applying the five docking methods, five different binding dispositions (best-scored docking pose) resulted from the docking of each ligand into each protein binding site. The RMSD of these docking poses against the remaining four was evaluated by using the rms_analysis software of the Gold suite. On this basis, for each ligand docked into the protein binding site, a 5 × 5 matrix was generated reporting the RMSD results. By using an in-house program [18] , these results were clustered, so that among the five results, all of the similar docking poses were clustered together. As a clustering algorithm, we used the complete-linkage method, which is an agglomerative type of hierarchical clustering. We selected an RMSD clustering threshold of 2.0 Å; therefore, the so-obtained clusters contained the group of poses that were less than 2.0 Å away from all others poses belonging to the same cluster. All of the ligands showing a consensus level of five were taken into account. MD simulations. All simulations were carried out using AMBER 14 [32] . MD simulations were performed using the ff14SB force field at 300 K. The complex was placed in a rectangular parallelepiped water box. Magnesium ion was inserted analyzing its disposition and interaction into the 2FN1 PDB code [33] . Many force field-based MD simulations of biological systems containing Mg 2+ have already been reported in literature [34] [35] [36] [37] . In the present study we used the particle mesh Ewald (PME) compatible Lennard-Jones parameters for divalent metal ions in explicit solvent reported by Merz and co-workers [38] .
An explicit solvent model for water, TIP3P, was used, and the complexes were solvated with a 20 Å water cap. Sodium ions were added as counterions to neutralize the system. Prior to MD simulations, two steps of minimization were carried out; in the first stage, we kept the protein fixed with a position restraint of 500 kcal/mol•Å 2 and we solely minimized the positions of the water molecules. In the second stage, we minimized the entire system through 5000 steps of steepest descent followed by conjugate gradient (CG) until a convergence of 0.05 kcal/Å•mol, using the same procedure described above. PME electrostatics and periodic boundary conditions were used in the simulation [39] . The MD trajectory was run using the minimized structure as the starting conformation. The time step of the simulations was 2.0 fs with a cutoff of 10 Å for the non-bonded interaction, and SHAKE was employed to keep all bonds involving hydrogen atoms rigid. Constant-volume periodic boundary MD was carried out for 0.5 ns, during which the temperature was raised from 0 to 300 K. Then 19.5 ns of constant pressure periodic boundary MD was performed at 300 K using the Langevin thermostat to maintain constant the temperature of our system. All the α carbons of the protein were blocked with a harmonic force constant of 10 kcal/mol•Å 2 for the first 3.5 ns while in the last 16.5 ns no constraints were applied. General Amber force field (GAFF) parameters were assigned to the ligands, while partial charges were calculated using the AM1-BCC method as implemented in the Antechamber suite of AMBER 14.
General Synthetic Procedures and Materials. Commercial products (1a,e and 4) , chemicals and solvents were of reagent grade; they were purchased from suppliers (Sigma-Aldrich) and used as received. Anhydrous solvents were utilized without further drying. Details about specific synthetic procedures and analytical data (Table S2) Compound 1m (1 mmol) was further treated with potassium hydroxide (4.5 mmol) in water (12 mL) at reflux for 6 h. After completion, the solution was acidified with hydrochloric acid (10M) and then extracted with ethyl acetate (3 x 7 mL). The organic layers were washed with brine, dried over anhydrous sodium sulfate and then concentrated in vacuo to obtain 1n as a light yellow solid. 1a-o, 2a, 3, 4 . All compounds were characterized using 1 H NMR, 13 
Characterization of

Equation 2
Pan Assay Interference Compounds (PAINS) analysis. As reported by Baell and Holloway, there is a number of substructural features which could help to identify compounds that appear as PAINS in many biochemical high-throughput screens [41, 42] .
The corresponding filters have been included in the Filter-it TM software and compound 1a was thus filtered by using this program. The result highlighted that this compound did not possess any of the substructural features shared by the most common PAINS. Moreover, to verify the possible formation of aggregates, the ability of compound 1a to inhibit MbtI activity was also tested in the presence of 0.1 mg/mL of bovine serum albumin (BSA) or in the presence of 0.01% (v/v) Triton X-100 as detergent [43] . As reported in Figure S93 , the IC50 value in the presence of BSA (7.28 ± 1.41 μM) or in the presence of Triton X-100 (8.00 ± 1.28 μM) are not significantly different, supporting the notion that the ligand did not act as an aggregate. Finally, to exclude a promiscuous enzyme inhibition due to covalent reaction with cysteines [44] . MbtI inhibition activity of compound 1a was also tested in the presence of 100 M of 1,4-dithio-DL-threitol (DTT). As depicted in Figure S93 , the IC50 was not influenced by DTT (7.84 ± 1.07 μM), thus excluding an interaction of 1a with the MbtI cysteines.
Minimal inhibitory concentration determinations. The MIC 99 of 1a and 2a, against M.
tuberculosis H37Rv, was determined in solid medium. A single colony was inoculated in complete Middlebrook 7H9 supplemented with 10% OADC Middlebrook Enrichment, and grown at 37 °C until exponential growth phase (~10 8 CFU/mL). Dilutions to the final concentration of ~10 6 CFU/mL were performed and about 1 µL of cell culture was streaked onto plates containing two-fold serial dilutions of appropriate compound. MIC values were assigned as the lowest drug concentrations inhibiting bacterial cell growth. The experiments were performed in triplicate. Additionally, the compound was assayed against M. bovis BCG in liquid medium, in high and low iron media, by determining the MIC against cells grown both in 7H9/OADC medium and in low-iron Chelated Sauton's medium [45] .
Siderophore production assay. Siderophore activity present in the culture was tested in M. bovis BCG through the isolation of mycobactins [46] or using the Universal CAS liquid assay [28] . To this purpose, M. bovis was grown in 7H9 medium, subcultured in chelated Sauton's medium, then diluted 1:1000 in chelated Sauton's containing different concentrations of compound 1a. After 15 days of incubation at 37°C, cells were harvested by centrifugation. For the isolation of mycobactins, cell pellets were extracted in ethanol overnight. 0.1 M FeCl3 in ethanol was added until no further change in colour was observed, and the mixture incubated at room temperature for 1 h. Mycobactins were then extracted in chloroform, washed with water 3 times to remove the excess of iron, and evaporated.
Residue was dissolved in methanol. The concentration of mycobactins was determined by measuring the absorbance at 450 nm (1% solution of mycobactins gives an absorbance of 42.8) [46] . For Universal CAS assay 100 l of cell cultures supernatant was mixed with 100 l of CAS assay liquid solution in 96 well plate, incubated 10 min at room temperature, then the absorbance was measured at 630 nm. The siderophore units were calculated using the following equation
where Ar is the absorbance at 630 nm of the blank medium with CAS assay solution and As is the absorbance of the culture supernatants with CAS assay solution.
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